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Medical Sciences and 11) Department of Occupational Health, School of Public Health, Medical Sciences, University of Tehran, Tehran, IranAbstractLittle is known about the toxin proﬁles, toxinotypes and variations of toxin Clostridioides difﬁcile C (tcdC) in Iranian C. difﬁcile isolates. A total of
818 stool specimens were obtained from outpatients (n = 45) and hospitalized patients (n = 773) in Tehran, Iran, from 2011 to 2017. The 44
C. difﬁcile isolates were subjected to PCR of toxin C. difﬁcile A (tcdA), toxin C. difﬁcile B (tcdB), tcdA 30-end deletion, toxinotyping and sequencing
of the tcdC gene. Thirty-eight isolates (86.36%) were identiﬁed as tcdA and tcdB positive, and the remaining six isolates (13.63%) were
nontoxigenic. All tcdA- and tcdB-positive isolates yielded an amplicon of 2535 bp by PCR for the tcdA 30 end. Fourteen (36.84%),
seventeen (44.73%) and seven (18.43%) isolates belonged to wild-type, toxin C. difﬁcile C subclone3 (tcdC-sc3) and tcdC-A genotype of
tcdC, respectively. Thirty-one isolates (81.57%) belonged to toxinotype 0, and seven isolates (18.42%) were classiﬁed as toxinotype V.
This study provides evidence for the circulation of historical and hypervirulent isolates in the healthcare and community settings.
Furthermore, it was also demonstrated that the tcdC-A genotype and toxinotype V are not uncommon among Iranian C. difﬁcile isolates.
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tums.ac.ir (M. Douraghi)IntroductionHistorically known as a primary aetiologic agent of nosocomial
antibiotic-associated diarrhoea, Clostridioides difﬁcile has recently
emerged in community settings [1–3]. C. difﬁcile infections arew Microbe and New Infect 2018; 25: 52–57
2018 Published by Elsevier Ltd
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ps://doi.org/10.1016/j.nmni.2018.07.003toxin mediated and are manifested clinically as a spectrum of
mild to life-threatening symptoms, from diarrhoea to pseudo-
membranous colitis [4]. An enterotoxin (toxin A, TcdA) and a
cytotoxin (toxin B, TcdB) are the main virulence determinants
of C. difﬁcile [5]. The cytotoxic activity of TcdB can lead to
diarrhoea, while progression of illness and initial damage of
colon are attributed to the enteropathy effects of TcdA [6].
Although the majority of toxigenic strains harbour TcdA and
TcdB (TcdA positive/TcdB positive), a proportion of strains
carry only TcdB (TcdA negative/TcdB positive) [7].
The genes encoding TcdA and TcdB are located on the
19.6 kb pathogenicity locus (PaLoc), which also contains three
open reading frames including toxin C. difﬁcile E (tcdE), toxin
C. difﬁcile R (tcdR) and tcdC. TcdC plays an important role as
negative regulator of TcdA and TcdB production [8]. Variousnses/by-nc-nd/4.0/)
NMNI Aliramezani et al. PaLoc in Iranian C. difﬁcile isolates 53alterations have been found in the PaLoc genes of C. difﬁcile
strains throughout the world, and these variations have
remarkable consequences on the structure and function of
TcdA and TcdC proteins. A notable alteration is the deletion of
1.8 kb within the 30 end of tcdA gene which gives rise to the
formation of TcdA-negative/TcdB-positive C. difﬁcile strains [9].
While such strains are potentially toxigenic, they could not be
detected by cytotoxicity assays because truncated TcdA lacks
the ligand-binding domain [7]. Changes in the C terminus of
TcdA (A3 fragment) and the N terminus of TcdB (B1 fragment)
toxins lead to the deﬁnition of 34 variants toxinotypes (I to
XXXIV). The most important toxinotypes that were isolated
from humans are toxinotype 0, III, IV, V and VIII. The nucleotide
polymorphisms in tcdC gene including mutations and/or de-
letions in coding regions may lead to premature stop codons
and consequently truncation of the functional TcdC protein.
The mutated TcdC might be associated with increased pro-
duction of TcdA and TcdB, and accordingly the virulence of
C. difﬁcile [10]. Little is known about the toxin proﬁles, tox-
inotyping, and variations of tcdC in of Iranian C. difﬁcile strains.
Therefore, we analysed the toxin proﬁles and variations in tcdA
and tcdC genes of C. difﬁcile strains recovered from patients with
diarrhoea.Materials and methodsSetting and isolates
This study was conducted at the anaerobic bacteriology labo-
ratory afﬁliated with the School of Public Health, Tehran Uni-
versity of Medical Sciences, Tehran, Iran. A total of 818 stool
specimens were obtained from outpatients (n = 45) and hos-
pitalized patients (n = 773). These patients were suspected of
having C. difﬁcile–associated diarrhoea and were referred to the
anaerobic bacteriology laboratory from 17 referral tertiary
hospitals or clinics located in different geographical areas of
Tehran, Iran, from 2011 to 2017 (Table 1). After alcohol shock,
stools were cultivated on cycloserine cefoxitin fructose agar
and were incubated anaerobically at 37°C for 48 hours. The
suspected colonies were identiﬁed as C. difﬁcile by colony
morphology, speciﬁc horse odor, Gram staining and
proline–aminopeptidase test [11].
PCR assays
Genomic DNA extraction of C. difﬁcile isolates was done using
Chelex 100 (Bio-Rad, Hercules, CA, USA) [12]. For molecular
identiﬁcation of C. difﬁcile isolates, we used gene-speciﬁc
primers targeting C. difﬁcile housekeeping genes including
triose phosphate isomerase (tpi), glutamate dehydrogenase
(gluD), C. difﬁcile upstream 2 (cdu2) and C. difﬁcile downstream 3This is an open access artic(cdd3) genes [13–15]. C. difﬁcile isolates were also screened for
toxin A (tcdA) and toxin B (tcdB) genes [15,16]. To conﬁrm
complete absence of PaLoc, all tcdA- and tcdB-negative strains
were tested with PCR using Lok1-Lok3 primers [17]. In addi-
tion, tcdA 30 end (tcdA30) deletion analysis was performed using
NK9 and NKV011 primers [18]. The entire tcdC gene of isolates
was ampliﬁed using C1 and C2 primers [16], and subsequently
the PCR products were subjected to sequencing.
Toxinotyping
All tcdA- and tcdB-positive isolates were subjected to tox-
inotyping using A3 and B1 primers that were previously
described [19].
Toxigenic culture
The toxigenic culture of C. difﬁcile isolates was performed as
follows: three to ﬁve colonies of a pure culture of bacteria were
subcultured on brain–heart infusion broth and incubated
anaerobically for 3 to 5 days at 37°C. After centrifugation and
ﬁltration, brain–heart infusion supernatant containing toxin was
added to a 96-well microplate containing 104 Vero cell line.
After examination of the cell line at 24 and 48 hours under 5%
CO2 at 37°C incubation conditions, cytopathic effects were
recorded if 50% or more of the Vero cells were rounded [20].
Nucleotide sequence accession number
The nucleotide sequences of tcdC gene variants including wild
type, truncated variant tcdC-A allele and tcdC-sc3 allele were
deposited in GenBank under the accession numbers, indicated
in Table 2.ResultsOf 818 stool samples from outpatients and hospitalized pa-
tients, 44 isolates (5.37%) were identiﬁed as C. difﬁcile based on
detection of tpi, gluD, cdu-2 or cdd-3 (Table 1). Mean and
standard deviation of patient age was 53.89 ± 22.44 years. Of
44 isolates, 38 (86.36%) were tcdA and tcdB positive and the
remaining 6 (13.63%) isolates were tcdA and tcdB negative and
nontoxigenic. All tcdA- and tcdB-negative isolates were positive
in PCR reaction using Lok1-Lok3 primers and had 769 bp
amplicon (Table 1).
Of the 38 tcdA- and tcdB-positive isolates, all isolates yielded
an amplicon of 2535 bp by PCR ampliﬁcation for the tcdA 30
end, thus conﬁrming no deletion at this region. Using NK9 and
NKV011 primers, six isolates that were tcdA and tcdB negative
also were negative in tcdA 30-end analysis. Of 38 toxigenic
isolates, 31 isolates (81.57%) belonged to toxinotype 0, and 7
(18.42%) were classiﬁed as toxinotype V (Table 1).© 2018 Published by Elsevier Ltd, NMNI, 25, 52–57
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
TABLE 1. Genetic proﬁles and molecular characteristic of Clostridioides difﬁcile isolates
No. Strain
Year of
isolation Sourcea cdu2/tpi/cdd3/gluD tcdA/tcdB Lok1/Lok3
tcdA 30
size (bp) tcdC
tcdC
deletion
(bp)
tcdC stop codon
at 184 bp CPE Toxinotype
1 PC002 2014 H +/+/+/+ +/+ − 2535 + 39 + + V
2 PC004 2014 H +/+/+/+ +/+ − 3100b + − − + 0
3 PC006 2014 H +/+/+/+ +/+ − 2535 + − − + V
4 PC008 2014 H −/+/+/+ +/+ − 3100b + 39 + + 0
5 PC009 2014 H +/+/+/+ +/+ − 3100b + 39 + + 0
6 PC010 2014 H +/+/+/+ +/+ − 2535 + − − + V
7 PC020 2014 H +/+/+/+ +/+ − 2535 + − − + 0
8 PC021 2014 H +/+/+/+ +/+ − 2535 + − − + 0
9 PC024 2014 H +/+/+/+ +/+ − 3100b + − − + 0
10 PC028 2015 H +/+/+/+ +/+ − 2535 + − − + 0
11 PC035 2015 H +/+/+/+ +/+ − 2535 + − − + 0
12 PC036 2015 H +/+/+/+ +/+ − 2535 + − − + 0
13 PC048 2015 H +/+/+/+ −/− + — − − − − -
14 PC049 2015 H +/+/+/+ +/+ − 2535 + − − + 0
15 PC054 2015 H +/+/+/+ +/+ − 2535 + − − + 0
16 PC056 2015 H +/+/+/+ +/+ − 2535 + − − + 0
17 PC062 2015 H +/+/+/+ +/+ − 2535 + 39 + + V
18 PC063 2015 O +/+/+/+ +/+ − 2535 + − − + 0
19 PC066 2015 H +/+/+/+ +/+ − 2535 + − − + 0
20 PC069 2016 O −/+/+/+ +/+ − 2535 + 39 + + V
21 PC071 2011 H +/+/+/+ +/+ − 2535 + − − + 0
22 PC073 2012 H +/+/+/+ −/− + — − − − − -
23 PC074 2011 H +/+/+/+ +/+ − 2535 + − − + 0
24 PC075 2011 H +/+/+/+ −/− + — − − − − -
25 PC080 2016 H +/+/+/+ −/− + — − − − − -
26 PC087 2016 H −/+/+/+ +/+ − 2535 + − − + 0
27 PC089 2016 H −/+/+/+ +/+ − 2535 + − − + 0
28 PC091b 2016 H +/+/+/+ −/− + — − − − − -
29 PC092b 2016 H −/+/+/+ +/+ − 2535 + − − + 0
30 PC096 2016 H −/+/+/+ +/+ − 2535 + 39 + + V
31 PC098 2016 H +/+/+/+ +/+ − 2535 + − − + 0
32 PC101 2016 H +/+/+/+ +/+ − 2535 + − − + 0
33 PC102 2016 H +/+/+/+ −/− + — − − − − -
34 PC103 2016 H +/+/+/+ +/+ − 2535 + − − + 0
35 PC106 2016 H +/+/+/+ +/+ − 2535 + 39 + + V
36 PC107 2016 H +/+/+/+ +/+ − 2535 + − − + 0
37 PC111 2016 H +/+/+/− +/+ − 2535 + − − + 0
38 PC112 2016 H +/+/+/+ +/+ − 2535 + − − + 0
39 PC113 2016 H +/+/+/− +/+ − 2535 + − − + 0
40 PC114 2016 H +/+/+/+ +/+ − 2535 + − − + 0
41 PC115 2016 H +/+/+/+ +/+ − 2535 + − − + 0
42 PC116 2016 H +/+/+/+ +/+ − 2535 + − − + 0
43 PC117 2016 H +/+/+/+ +/+ − 2535 + − − + 0
44 PC118 2017 H +/+/+/+ +/+ − 2535 + − − + 0
aHospitalized patients (H) or outpatients (O).
bAmplicon was obtained using A3C and A4N primers [19].
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had no deletion in tcdC sequences and were assigned to the
wild-type tcdC genotype. Seventeen isolates (44.73%) contained
a G/ T transition at nucleotide 148 and belonged to tcdC-sc3
genotype. Seven isolates (18.43%) had deletion of 39 bp and
also a C/ T transition at nucleotide 184, and represented the
tcdC-A genotype. The latter transition is proposed to result in
truncation of the TcdC protein (Table 2).DiscussionWe found that 5% of patients harboured C. difﬁcile as either
toxigenic or nontoxigenic isolates. This proportion is concor-
dant with the previous report from Tehran, Iran, using enzyme-
linked immunosorbent assay [21]. Using PCR for detection of
tcdA and tcdB, we demonstrated that the majority of C. difﬁcile
isolates harboured tcdA and tcdB genes (Table 1). On the other© 2018 Published by Elsevier Ltd, NMNI, 25, 52–57
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licehand, the isolates with no amplicon for tcdA/tcdB were
conﬁrmed to be nontoxigenic by a positive assay yielding an
amplicon of 769 bp using Lok1 and Lok3 (Table 1) [17]. The
frequency of toxigenic isolates tested in the current study
(86.36%) was slightly higher than another study (84.2%) re-
ported from Tehran, Iran [22]. In neighbouring countries such
as Kuwait, the rate of toxigenic C. difﬁcile was reported to be
0.54% to 64.6% [23,24]. This difference might be partly related
to the sample size, the target population and mainly to the
primer set used in the current study. We used the primers
targeting the 50 end of the tcdA gene [15] and amplifying the
conserved region and nonrepeating fragment of tcdA. Using this
set of primers, all but the nontoxigenic isolates yielded ampli-
cons, and as expected, the negative result for PCR was unlikely
unless the isolates had a large deletion in tcdA [15]. Therefore,
the isolates harbouring the tcdA gene was subsequently assayed
for tcdA deletion in the 30 end. Analysis of the 30 end of tcdA
revealed that all the isolates except four (PC004, PC008,nses/by-nc-nd/4.0/).
TABLE 2. tcdC genotypes of Clostridioides difﬁcile isolates
No. Strain Mutation (nucleic acid residues) tcdC genotype
GenBank
accession no.
1 PC002 G/ T (53)/A/ T (117)/C/ T (120)/C/ T (183)/C/ T (184) (stop codon)/A/ G (330)/G/ T (430)/
A/ C (516)/T/ A (558) (stop codon)/T/ A (585)/T/ C (660)/39bp deletion (341–379)
tcdC-A MG675257
2 PC004 G/ T (148) tcdC-sc3 MG675248
3 PC006 G/ T (148) tcdC-sc3 MG675249
4 PC008 — Wild type MG675253
5 PC009 G/ T (53)/A/ T (117)/C/ T (120)/C/ T (183)/C/ T (184) (stop codon)/A/ G (330)/G/ T (430)/
A/ C (516)/T/ A (558) (stop codon)/T/ A (585)/T/ C (660)/39bp deletion (341–379)
tcdC-A MG675258
6 PC010 G/ T (53)/A/ T (117)/C/ T (120)/C/ T (183)/C/ T (184) (stop codon)/A/ G (330)/G/ T (430)/
A/ C (516)/T/ A (558) (stop codon)/T/ A (585)/T/ C (660)/39bp deletion (341–379)
tcdC-A MG675259
7 PC020 G/ T (148) tcdC-sc3 MG569922
8 PC021 G/ T (148) tcdC-sc3 MG675250
9 PC024 — Wild typea MG596349
10 PC028 — Wild type MG596350
11 PC035 G/ T (148) tcdC-sc3 MG655373
12 PC036 G/ T (148) tcdC-sc3 MG655374
13 PC049 G/ T (148) tcdC-sc3 MG655375
14 PC054 G/ T (148) tcdC-sc3 MG675251
15 PC056 G/ T (148) tcdC-sc3 MG655376
16 PC062 G/ T (53)/A/ T (117)/C/ T (120)/C/ T (183)/C/ T (184) (stop codon)/A/ G (330)/G/ T (430)/
A/ C (516)/T/ A (558) (stop codon)/T/ A (585)/T/ C (660)/39bp deletion (341–379)
tcdC-A MG581978
17 PC063 G/ T (148) tcdC-sc3 MG655377
18 PC066 G/ T (148) tcdC-sc3 MG675238
19 PC069 G/ T (53)/A/ T (117)/C/ T (120)/C/ T (183)/C/ T (184) (stop codon)/A/ G (330)/G/ T (430)/
A/ C (516)/T/ A (558) (stop codon)/T/ A (585)/T/ C (660)/39bp deletion (341–379)
tcdC-A MG675239
20 PC071 G/ T (148) tcdC-sc3 MG675240
21 PC074 — Wild type MG675241
22 PC087 G/ T (148) tcdC-sc3 MG675242
23 PC089 — Wild type MG675243
24 PC092b — Wild type MG675244
25 PC096 G/ T (53)/A/ T (117)/C/ T (120)/C/ T (183)/C/ T (184) (stop codon)/A/ G (330)/G/ T (430)/
A/ C (516)/T/ A (558) (stop codon)/T/ A (585)/T/ C (660)/39bp deletion (341–379)
tcdC-A MG675245
26 PC098 G/ T (148) tcdC-sc3 MG675246
27 PC101 G/ T (148) tcdC-sc3 MG675247
28 PC103 — Wild type MG675255
29 PC106 G/ T (53)/A/ T (117)/C/ T (120)/C/ T (183)/C/ T (184) (stop codon)/A/ G (330)/G/ T (430)/
A/ C (516)/T/ A (558) (stop codon)/T/ A (585)/T/ C (660)/39bp deletion (341–379)
tcdC-A MG675260
30 PC107 — Wild type MG675256
31 PC111 — Wild type MG788278
32 PC112 — Wild type MG788279
33 PC113 — Wild type MG788280
34 PC114 G/ T (148) tcdC-sc3 MG788284
35 PC115 G/ T (148) tcdC-sc3 MG788285
36 PC116 — Wild type MG788281
37 PC117 — Wild type MG788282
38 PC118 — Wild type MG788283
CPE, cytopathic effects.
aPublished sequence of Clostridioides difﬁcile strain VPI10463 was used as reference strain for comparison of all sequences [34].
NMNI Aliramezani et al. PaLoc in Iranian C. difﬁcile isolates 55PC009, PC024) produced an amplicon of 2535 bp using primers
NK9-NKV011 (Table 1) [18]. While no amplicon was observed
for the latter four isolates in PCR of the 30 end, the amplicons of
3100 bp were noted using the primers directed at the A3
fragment used for toxinotyping [19]. Altogether, the isolates
with a 2535 bp amplicon or 3100 bp were considered ToxA+/
ToxB+ (Table 1).
Toxinotyping of tcdA- and tcdB-positive isolates showed
that these isolates belonged to toxinotype 0 or V. The most
predominant toxinotype in our study was toxinotype 0, and
this toxinotype showed no changes in tcdA and tcdB gene
sequences (Table 1) [19]. Previous studies indicated that the
C. difﬁcile isolates with the entire repeating region of tcdA had
toxinotype 0 and V [25,26]. Jalali et al. [27] also found that
toxinotype 0 was the prevalent toxinotype in an Iranian
hospital. The most frequent toxinotypes in Asia are tox-
inotype 0 and VIII [24,28]. Two studies reported that 71.4%
and 7.69% of C. difﬁcile toxinotypes in different hospitals in
Kuwait and Lebanon belonged to toxinotype 0, respectivelyThis is an open access artic[24,29]. These data show the minor changes in PaLoc either
in Iran or Asia.
With respect to clinical manifestations, either the non-
toxigenic or toxigenic isolates were recovered from symptom-
atic patients who had diarrhoea. One possible explanation for
recovery of the nontoxigenic C. difﬁcile isolates might be the
presence of such isolates as a member of intestinal microbiota
[30]. In other words, the clinical manifestations may not be
associated with the colonization of intestine by C. difﬁcile or its
carriage by patients, and only the intake of antibiotics may
contribute to the development of antibiotic-associated diarrhoea
[31]. For instance, one of the nontoxigenic isolates was recov-
ered from a 54-year-old woman with HIV and toxoplasmosis.
This patient was hospitalized for a long period, was subjected to
the antimicrobial therapies and ﬁnally died. The patient had
several predisposing factors, but it is difﬁcult to concludewhether
the nontoxigenic isolate was signiﬁcantly implicated in diarrhoea.
Another explanation is that apart from toxins, other virulence
factors of C. difﬁcile, particularly the colonization factors, may© 2018 Published by Elsevier Ltd, NMNI, 25, 52–57
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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consequently give rise to disease. It has been reported that up to
50% of C. difﬁcile isolated from healthy volunteers and asymp-
tomatic hospitalized patients were nontoxigenic strains.
Although there are several case reports describing the possible
role of nontoxigenic isolates as risk or protective factor [33],
further studies are needed to assess the function of nontoxigenic
isolates in inducing C. difﬁcile–associated clinical outcomes.
We identiﬁed three types of tcdC genes in our isolates using
sequencing: wild type, tcdC-A and tcdC-sc3 genotypes. The tcdC-A
genotype is characterized by the existence of nonsense muta-
tion at nucleotide 184 and 39 bp deletion at nucleotides 341 to
379 [34]. Toxinotyping revealed that all the isolates that had
39 bp deletion in tcdC gene belonged to toxinotype V, except
two isolates. The isolates with no changes in tcdC gene were
classiﬁed as toxinotype 0 except two isolates that belonged to
toxinotype V (Tables 1 and 2). Isolates with TcdC truncation
and toxinotype V may cause severe infections in humans and
animals and may be identiﬁed as hypervirulent strains [35].
Hypervirulent C. difﬁcile strains also express binary toxins (cdtA
and cdtB) that may increase the severity of disease [35]. Little is
known about the heterogenicity of C. difﬁcile toxin genes in
Iranian isolates, especially in Tehran. Jalali et al. [27] found that
0, V and XXIV toxinotypes were predominant in Isfahan. In our
study, the six isolates with tcdC-A genotype were also positive
for binary toxin (cdtA, cdtB) except one isolate using gene-
speciﬁc PCR (data not shown). These six cdtA- and cdtB-posi-
tive isolates also belonged to toxinotype V. Six isolates of tcdC-A
genotype were obtained from hospitalized patients and one
from an outpatient (Tables 1 and 2). Jalali et al. [27] also re-
ported that the isolates that possess 39 bp deletion in tcdC gene
belonged to toxinotype V isolated from hospitalized patients.
Persson et al. [15] and Spigaglia et al. [16] reported that all the
isolates that have a 39 bp deletion in tcdC gene may belong to
toxinotypes V, VI and VII. Among the tcdC genotypes, the tcdC-
sc3 genotype has the highest frequency, as reported in other
studies (Table 2) [34,]. This study provides molecular evidence
that the isolates with either toxigenic or nontoxigenic proﬁles
are circulating in the healthcare and community settings.
Furthermore, it was also demonstrated that the tcdC-A geno-
type and toxinotype V is not uncommon among Iranian
C. difﬁcile isolates. This ﬁnding sheds light on the possibility of
the contribution of hypervirulent isolates in C. difﬁcile infections
in addition to historical isolates of C. difﬁcile.AcknowledgementSupported in part by grant 31372 from Tehran University of
Medical Sciences and Health Services.© 2018 Published by Elsevier Ltd, NMNI, 25, 52–57
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